TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17442840

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Strength training (ST)
Number of subjects: 74
Study: 15572280

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (active injections, dummy oral)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Oral risperidone (dummy injections, active oral)
Number of subjects: 640
Study: 11988132

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate with 0.625 mg conjugated equine estrogens (CEE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cyclic etidronate with 0.625 mg CEE
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg alendronate with 2 mg estradiol (E2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tibolone with fluoride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent etidronate with fluoride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination regimens (nandrolone decanoate plus calcitonin, calcitonin plus growth hormone (GH), pamidronate plus GH)
Number of subjects: 24
Study: 9808143

Group type: EXPERIMENTAL
Intervention: 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol) intravenously at doses ranging from 0.04 to 0.24 microg/kg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol) at 0.16 and 0.24 microg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 19-nor-1,25-dihydroxyvitamin D2 (paricalcitol) and Placebo
Number of subjects: 35
Study: 7702151

Group type: EXPERIMENTAL
Intervention: neuroleptanaesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: sevoflurane‐based anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: both anaesthesia techniques
Number of subjects: 20
Study: 29335386

Group type: EXPERIMENTAL
Intervention: CorPath GRX system
Number of subjects: 40
Study: 27589047

Group type: EXPERIMENTAL
Intervention: Rolofylline
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2033
Study: 24748179

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided procedure
Number of subjects: 214

Group type: COMPARATOR
Intervention: Seldinger's technique
Number of subjects: 214
Study: 28075228

Group type: EXPERIMENTAL
Intervention: Systematic screening
Number of subjects: 141578

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 141578
Study: 20568377

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of oral prednisone daily for 2 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 18436033

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg/0.5 mg naloxone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pentazocine 50 mg/0.5 mg naloxone (females)
Number of subjects: 43
Study: 16965204

Group type: EXPERIMENTAL
Intervention: Early Behavioral Intervention (EBI), N = 35
Number of subjects: 61

Group type: COMPARATOR
Intervention: Routine Care Intervention (RCI), N = 27
Number of subjects: 61
Study: 14576659

Group type: EXPERIMENTAL
Intervention: Alefacept (7.5 mg intravenously weekly for 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (standard immunization schedule)
Number of subjects: 100
Study: 10737581

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenously at induction of anesthesia
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 9014625

Group type: EXPERIMENTAL
Intervention: Propofol 3 mg kg‐1 followed by a 9‐mg kg‐1 h‐1 continuous infusion
Number of subjects: 37

Group type: COMPARATOR
Intervention: Thiopentone 4 mg kg‐1 followed by a 15‐mg kg‐1 h‐1 continuous infusion
Number of subjects: 37

Group type: COMPARATOR
Intervention: Thiopentone group
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Propofol group
Number of subjects: 37
Study: 1515878

Group type: EXPERIMENTAL
Intervention: Regimen A (TBI dose 9 Gy)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Regimen B (increased TBI dose rate and anthracyclines)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Regimen C (TBI dose 12 Gy, no anthracyclines)
Number of subjects: 144
Study: 3924719

Group type: EXPERIMENTAL
Intervention: Misoprostol 800 micrograms/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine 1.2 g/day
Number of subjects: 0
Study: 31407775

Group type: COMPARATOR
Intervention: Nasal cast with elastic bandage (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vibration treatment in addition to nasal cast with elastic bandage (group 3)
Number of subjects: 60
Study: 29997457

Group type: EXPERIMENTAL
Intervention: Bacillus coagulans MTCC 5856
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28606184

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI)
Number of subjects: 2550

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2550
Study: 26562491

Group type: EXPERIMENTAL
Intervention: Recruitment strategies in the PLEASANT trial
Number of subjects: 142
Study: 23767097

Group type: EXPERIMENTAL
Intervention: Emoxipin (150 mg, two-week infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reamberin (400 ml, two-week infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mexidol (300 mg, two-week infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20352318

Group type: EXPERIMENTAL
Intervention: Diaphragm with lubricant gel
Number of subjects: 4925

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4925

Group type: EXPERIMENTAL
Intervention: Vaginal practices (washing, wiping, insertion of dry or absorbent materials)
Number of subjects: 4925

Group type: EXPERIMENTAL
Intervention: Washing, wiping, and insertion practices
Number of subjects: 4925
Study: 18822903

Group type: EXPERIMENTAL
Intervention: Bushen Jianpi Recipe (BSJPR)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Liver protecting remedy (silymarin and vitamin C)
Number of subjects: 117
Study: 16874758

Group type: EXPERIMENTAL
Intervention: Transcranial sonography (TCS)
Number of subjects: 42
Study: 12514673

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN) 60 mg daily for 11 months
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 11104176

Group type: EXPERIMENTAL
Intervention: Shared mental models organization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Degree of overlap between team members' mental models
Number of subjects: 0
Study: 9015908

Group type: EXPERIMENTAL
Intervention: Nisoldipine coat-core (10, 20, 40 mg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Atenolol (50, 100 mg)
Number of subjects: 230
Study: 1726000

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacidipine 2 mg once daily
Number of subjects: 0
Study: 6738365

Group type: EXPERIMENTAL
Intervention: 15 mg/kg/day ursodeoxycholic acid
Number of subjects: 16

Group type: COMPARATOR
Intervention: 15 mg/kg/day lactose
Number of subjects: 16
Study: 30545532

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) infusion (0.5-1 cc) in addition to HRT
Number of subjects: 83

Group type: COMPARATOR
Intervention: Hormone replacement therapy (HRT) only
Number of subjects: 83
Study: 27481035

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of inspiratory muscle training and functional electrical stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study: 24139708

Group type: EXPERIMENTAL
Intervention: LCP‐I programme
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control wards (standard health-care practice)
Number of subjects: 308
Study: 23566914

Group type: EXPERIMENTAL
Intervention: Fractionated 20% 5-aminolevulinic acid (ALA) photodynamic therapy (PDT)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Surgical excision
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fractionated 20% 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) for tumors >0.7 mm
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Fractionated 20% 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) for tumors ≤0.7 mm
Number of subjects: 151
Study: 20526194

Group type: EXPERIMENTAL
Intervention: Casopitant 50 mg + Ondansetron 4 mg
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Casopitant 100 mg + Ondansetron 4 mg
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Casopitant 150 mg + Ondansetron 4 mg
Number of subjects: 702

Group type: COMPARATOR
Intervention: Ondansetron 4 mg alone
Number of subjects: 702
Study: 19055987

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose (LD) / 75 mg maintenance dose (MD) for 28 days
Number of subjects: 110

Group type: COMPARATOR
Intervention: Prasugrel 60 mg loading dose (LD) / 10 mg maintenance dose (MD) for 28 days
Number of subjects: 110
Study: 17285082

Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy with intersphincteric dissection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local resection through a trans-anal approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Future strategies
Number of subjects: 0
Study: 15239618

Group type: EXPERIMENTAL
Intervention: Celsior (CEL) solution
Number of subjects: 441

Group type: COMPARATOR
Intervention: University of Wisconsin (UW) solution
Number of subjects: 441
Study: 11300450

Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Active pedal plantarflexion
Number of subjects: 50
Study: 9278210

Group type: EXPERIMENTAL
Intervention: Troleandomycin (TAO), 250 mg daily for 2 days
Number of subjects: 0
Study: 8220156

Group type: EXPERIMENTAL
Intervention: Cytarabine 200 mg/m2/day by continuous infusion for seven days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cytarabine 500 mg/m2 every 12 hours for 12 doses (intermediate-dose)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Age > 60
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Age <= 60
Number of subjects: 102
Study: 3308980

Group type: EXPERIMENTAL
Intervention: Amikacin alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amikacin in combination with trimethoprim-sulfamethoxazole
Number of subjects: 15
Study: 29397146

Group type: EXPERIMENTAL
Intervention: Intervention group (received placemats featuring healthy 'Kids' Meals of the Day')
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no placemats)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Children who ordered a promoted healthy entrée
Number of subjects: 58
Study: 27328486

Group type: EXPERIMENTAL
Intervention: Desogestrel (DSG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 21 days followed by seven days of EE 10 mcg (21/7‐active)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Desogestrel (DSG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 21 days followed by no treatment (DSG/EE+no Tx)
Number of subjects: 246
Study: 24953836

Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22659624

Group type: EXPERIMENTAL
Intervention: bivalirudin 0.5 mg/kg intravenous bolus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: bivalirudin 0.75 mg/kg intravenous bolus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: bivalirudin 1.05 mg/kg intravenous bolus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: bivalirudin 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg intravenous infusion per hour for 4 h
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: bivalirudin
Number of subjects: 36
Study: 20924150

Group type: EXPERIMENTAL
Intervention: Vinegar drink (100 mL containing 750 mg acetic acid)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vinegar capsules (9 capsules containing 750 mg acetic acid in total with 150 mL of water)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference (150 mL of water)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison of AUC(capsule-ref) and AUC(drink-ref)
Number of subjects: 30
Study: 18410888

Group type: EXPERIMENTAL
Intervention: Bioelectric impedance (BIA) during hemodialysis sessions
Number of subjects: 7
Study: 16190386

Group type: EXPERIMENTAL
Intervention: Continuous pulmonary artery perfusion with oxygenated blood during CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine procedure of mitral valve replacement (Control)
Number of subjects: 30
Study: 12028517

Group type: EXPERIMENTAL
Intervention: Altruistic reason for participation
Number of subjects: 43

Group type: COMPARATOR
Intervention: Self-rewarding reasons for participation
Number of subjects: 43
Study: 10690113

Group type: EXPERIMENTAL
Intervention: Multidimensional stress management program
Number of subjects: 0
Study: 8700339

Group type: EXPERIMENTAL
Intervention: 30 mg piroxicam cinnamate (Sinartrol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20 mg piroxicam cinnamate
Number of subjects: 60
Study: 1833543

Group type: EXPERIMENTAL
Intervention: 5 ml lignocaine, 0.5% (L)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 5 ml isotonic saline (S)
Number of subjects: 41
Study: 6227296

Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole (ASA/DPM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 30920059

Group type: EXPERIMENTAL
Intervention: Nd‐YAG 1064 nm laser treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 64
Study: 28283863

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU every 2 weeks for 12 weeks)
Number of subjects: 60
Study: 26942475

Group type: EXPERIMENTAL
Intervention: Low anterior‐inferior rotator interval portal (AI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Trans‐subscapularis portal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mean pullout strength at the 5:30 position (trans‐subscapularis)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mean pullout strength at the 5:30 position (AI)
Number of subjects: 10
Study: 25500129

Group type: EXPERIMENTAL
Intervention: Stage tailored intervention (feedback letters tailored to motivational stage)
Number of subjects: 629

Group type: COMPARATOR
Intervention: Minimal assessment only (control group)
Number of subjects: 629
Study: 23132800

Group type: EXPERIMENTAL
Intervention: Group 2 (10 mg lutein, 2 mg zeaxanthin, and 10 mg meso-zeaxanthin)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group 1 (20 mg lutein and 2 mg zeaxanthin)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (Group 3)
Number of subjects: 36
Study: 20075646

Group type: EXPERIMENTAL
Intervention: Topiramate (25‐50 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Risperidone (0.5‐2 mg/d)
Number of subjects: 48
Study: 18480522

Group type: EXPERIMENTAL
Intervention: PCEA using fentanyl and bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: IVPCA using morphine
Number of subjects: 30
Study: 16163151

Group type: EXPERIMENTAL
Intervention: Blunt pins pressure during intramuscular injections
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Blunt pins pressure during subcutaneous injections
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo device during intramuscular injections
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo device during subcutaneous injections
Number of subjects: 212
Study: 12051399

Group type: COMPARATOR
Intervention: Diclofenac 150 mg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rofecoxib 25 mg/day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Amtolmetin guacyl (AMG) 1,200 mg over the first 3 days and 600 mg/day thereafter
Number of subjects: 90
Study: 10029968

Group type: EXPERIMENTAL
Intervention: Advance Laser Flowmeter Model 21; tested under conditions with teeth in situ and extracted, or with pulp present and removed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advance Laser Flowmeter Model 21; tested with teeth in situ.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advance Laser Flowmeter Model 21; tested on lingual and labial surfaces of teeth.
Number of subjects: 0
Study: 7733183

Group type: EXPERIMENTAL
Intervention: FOS-90 group (90 mg/kg of body weight/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: FOS-120 group (120 mg/kg of body weight/day)
Number of subjects: 18
Study: 1706023

Group type: EXPERIMENTAL
Intervention: Automatic blood pressure measurement device (A)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Auscultatory-mercury manometer (M)
Number of subjects: 440
Study: 6621617

Group type: EXPERIMENTAL
Intervention: BAY h 4502 (bifonazole) 1% cream/lotion applied once daily for 14 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% miconazole cream applied twice daily
Number of subjects: 60
Study: 31556937

Group type: EXPERIMENTAL
Intervention: 20 g of dark chocolate containing 400 mg of flavanols
Number of subjects: 22

Group type: COMPARATOR
Intervention: 7.5 g of milk chocolate
Number of subjects: 22
Study: 30024861

Group type: EXPERIMENTAL
Intervention: Adjuvanted varicella-zoster virus (VZV) glycoprotein E (gE) subunit herpes zoster vaccine (HZ/su)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Live attenuated zoster vaccine (ZV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 0
Study: 27836009

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200-1000 μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24048909

Group type: EXPERIMENTAL
Intervention: Aquatic Exercise Group (AEG), n = 64, performing 24 weeks of aquatic exercises
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control Group (CG), n = 44, sedentary
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Aquatic Exercise Group (AEG)
Number of subjects: 108
Study: 22451440

Group type: EXPERIMENTAL
Intervention: Intensified exercises (e.g. rubber band resistance) for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard rehabilitation exercises without external resistance for 12 weeks
Number of subjects: 46
Study: 20158297

Group type: EXPERIMENTAL
Intervention: Progesterone 50 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Progesterone 100 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 44
Study: 20418768

Group type: EXPERIMENTAL
Intervention: Buttonhole needling
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional rope-ladder needling
Number of subjects: 47
Study: 15757769

Group type: EXPERIMENTAL
Intervention: Intravenous flucloxacillin on induction followed by an oral placebo (Group A)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Intravenous flucloxacillin on induction followed by an oral flucloxacillin course (Group B)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Oral placebo (Group C)
Number of subjects: 157
Study: 12130606

Group type: EXPERIMENTAL
Intervention: Group based exercise
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: All three interventions combined (group based exercise, home hazard management, vision improvement)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Home hazard management
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Vision improvement
Number of subjects: 1090
Study: 10181572

Group type: EXPERIMENTAL
Intervention: Cognitive services performed by pharmacists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Financial incentives for pharmacists
Number of subjects: 0
Study: 7846339

Group type: EXPERIMENTAL
Intervention: Air filtration units (AFUs) with high efficiency particulate air filter
Number of subjects: 12
Study: 3072661

Group type: EXPERIMENTAL
Intervention: Silimarina (Legalon)
Number of subjects: 180
Study: 29191873

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (intervention group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no endovascular therapy)
Number of subjects: 59
Study: 27924798

Group type: EXPERIMENTAL
Intervention: Sulfate-rich mineral water (1 l/day for 6 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sulfate-rich mineral water (1 l/day for 3 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Carbonated tap water (placebo, 1 l/day for 6 weeks)
Number of subjects: 100
Study: 23897022

Group type: EXPERIMENTAL
Intervention: High-speed power training (HSPT) at 40% of 1RM
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Traditional slow-speed strength training (SSST) at 80% of 1RM
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 72
Study: 22118842

Group type: EXPERIMENTAL
Intervention: Omentectomy added to laparoscopic Roux-en-Y gastric bypass
Number of subjects: 28

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass alone
Number of subjects: 28
Study: 19897341

Group type: EXPERIMENTAL
Intervention: OPUS treatment
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 280
Study: 17965836

Group type: EXPERIMENTAL
Intervention: CoaguChek S
Number of subjects: 16

Group type: COMPARATOR
Intervention: INRatio
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 16
Study: 15983143

Group type: EXPERIMENTAL
Intervention: Incremental concentrations of sevoflurane (1% to 8%)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Decremental-incremental concentrations of sevoflurane (8% to 4% to 8%)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Fixed concentration of sevoflurane (8%)
Number of subjects: 131
Study: 12918553

Group type: EXPERIMENTAL
Intervention: Wrapped hydroxyapatite implant
Number of subjects: 15

Group type: COMPARATOR
Intervention: Unwrapped hydroxyapatite implant
Number of subjects: 15
Study: 10945031

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: LV.5-FU
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF combination therapy
Number of subjects: 0
Study: 8559367

Group type: EXPERIMENTAL
Intervention: Silent brain infarcts
Number of subjects: 985